IDO1 and neoplasm: Activation of IDO1 in the KYN pathway has been reported to suppress the T cell immune response by activating or differentiating regulatory T lymphocytes (Treg), which can inhibit the proliferation of other T cells and thus prevent anti-tumor responses.